Supplementary Material for: Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
Kreuter M.
Spagnolo P.
Wuyts W.
Renzoni E.
Koschel D.
Bonella F.
Maher T.M.
Kolb M.
Weycker D.
Kirchgässler K.-U.
Costabel U.
10.6084/m9.figshare.4858316.v1
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Antacid_Therapy_and_Disease_Progression_in_Patients_with_Idiopathic_Pulmonary_Fibrosis_Who_Received_Pirfenidone/4858316
<p><b><i>Background:</i></b> Gastroesophageal reflux disease is a
potential risk factor for idiopathic pulmonary fibrosis (IPF)
progression; however, the impact of antacid therapy (AAT) is under
debate. <b><i>Objective:</i></b> To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients. <b><i>Methods:</i></b>
This post hoc analysis included patients with IPF who received
pirfenidone in 3 trials (CAPACITY [PIPF-004/PIPF-006] and ASCEND
[PIPF-016]). Pulmonary function, exercise tolerance, survival,
hospitalizations, and adverse events (AEs) over 52 weeks were analyzed
by baseline AAT use. Disease progression was defined as a decrease in
forced vital capacity (FVC) of ≥10%, a decrease in 6-min walking
distance of ≥50 m, or death over 1 year. <b><i>Results:</i></b> Of 623
patients, 44% received AAT. No significant differences were found at 52
weeks (AAT versus non-AAT, respectively) in disease progression (24.9
vs. 30.6%; <i>p</i> = 0.12), all-cause mortality rate (2.9 vs. 4.0%; <i>p</i> = 0.47), IPF-related mortality rate (1.1 vs. 2.0%; <i>p</i> = 0.37), all-cause hospitalization rate (16.1 vs. 18.3%; <i>p</i> = 0.48), or mean change in percent FVC (-2.7 vs. -3.1%; <i>p</i> = 0.44). A relative, but not absolute, FVC decline of ≥10% favored AAT (15 vs. 22%; <i>p</i> = 0.03). Severe gastrointestinal AEs (3.7 vs. 0.9%; <i>p</i> = 0.015) and severe pulmonary infections (3.7 vs. 1.1%; <i>p</i> = 0.035) were more frequent with AAT. <b><i>Conclusions:</i></b>
AAT and pirfenidone had outcomes comparable to those of pirfenidone
alone in patients with IPF, underscoring the need for prospective trials
to elucidate the role of AAT with or without antifibrotic drugs as a
treatment for IPF.</p>
2017-04-11 13:45:14
Antacid therapy
Gastroesophageal reflux disease
Idiopathic pulmonary fibrosis
Pirfenidone
Progression-free survival